Lucid Diagnostics
At Lucid Diagnostics, we believe early detection will make esophageal cancer a disease of the past. We're using next generation sequencing to fundamentally change the way esophageal precancer is detected.
Who we are - LucidDX
We are a medical diagnostics company advancing groundbreaking technologies to revolutionize cancer prevention. Our innovative, non-invasive technologies are transforming the detection of esophageal precancer, empowering clinicians and enabling timely interventions.
Lucid Diagnostic Investor Relations - Overview
2021年10月15日 · Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
Esoguard - LucidDX
The EsoGuard Esophageal DNA Test assesses signature epigenetic changes indicative of BE and EAC using advanced molecular diagnostic techniques.
Lucid Diagnostics Announces Peer-Reviewed Publication of …
2023年12月12日 · Lucid's EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer ...
Lucid Diagnostics Launches Next-Generation EsoGuard® …
2023年11月9日 · Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower costs
Lucid Diagnostics Provides Business Update and Second Quarter …
2024年8月12日 · Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results EsoGuard ® test volume increased 31 percent quarterly; 44 percent annually Clinical data now well-positioned for final push towards broad coverage and reimbursement
Careers - LucidDX
We're a team of trailblazers, pioneers, innovators, groundbreakers, and changemakers. At Lucid, you'll revolutionize patient care with cutting-edge diagnostic solutions. We're seeking passionate professionals ready to make a lasting impact.
Lucid Diagnostics Provides Business Update and Preliminary …
2024年3月25日 · Lucid now has publicly-released data from three clinical validity studies demonstrating excellent EsoGuard sensitivity and negative predictive value, including unprecedented performance of a molecular diagnostic test in detecting precancer.
Lucid Diagnostics Launches New Corporate Website
2024年7月11日 · "We designed the new website to highlight our mission to prevent esophageal cancer and offer patients, healthcare professionals, investors, and other interested parties a user-friendly experience with easily accessible, informative content on Lucid and its innovative technologies," said Jenna Mowatt, Vice President of Marketing and ...